摘要
fondaparinux是一个化学合成的全新戊聚糖化合物 ,能够有效地预防大型的下肢骨科手术后常见的静脉血栓栓塞。本文就其药效学、药动学、临床应用及其现状等作一综述。
Fondaparinux, a selective factor Xa inhibitor, is a new pentasaccharide obtained by chemical synthesis. It binds selectively with high affinity to antithrombin Ⅲ and specifically catalyses the inactivation of factor Xa. It has been demonstrated that fondaparinux can significantly reduce the incidence of venous thromboembolism and be well tolerated by patients undergoing major orthopaedic surgery. This review focuses on the pharmacodynamics, pharmacokinetics and therapeutic trial of fondaparinux, so as to prevent venous thromboembolism in patients undergoing major orthopaedic surgery.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2004年第9期624-627,共4页
Chinese Journal of New Drugs and Clinical Remedies